- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00610675
Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)
September 4, 2018 updated by: Merck Sharp & Dohme LLC
Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002.
This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706) (NCT00482612) or 176002 (P05707) (NCT00506389).
Participants who have completed Protocol P05706 or P05707, and are willing to continue treatment with Esmirtazapine, can participate in Protocol 176004 (P05708) after signing informed consent.
Study Overview
Study Type
Interventional
Enrollment (Actual)
346
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- sign written informed consent after the scope and nature of the investigation have been explained to them, before any trial-related evaluations;
- completed Protocol P05706 or P05707;
- Have safety and efficacy assessments conducted per protocol P05706 or P05707.
Exclusion Criteria:
- clinically relevant electrocardiogram (ECG) abnormalities as judged by the investigator;
- clinically relevant abnormal laboratory values as judged by the investigator;
- any adverse event deemed relevant for exclusion in Protocol P05708 as judged by the investigator or,
- were significantly non compliant with protocol criteria and procedures of Protocol P05706 or P05707, as judged by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Esmirtazapine
One tablet of Esmirtazapine, 4.5 mg orally, daily for up to 52 weeks
|
One tablet daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With an Adverse Event
Time Frame: Up to 57 weeks
|
An Adverse Event (AE) is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an investigational medicinal product (IMP), whether or not it is related to the IMP.
|
Up to 57 weeks
|
Number of Participants Who Discontinued Treatment Due to an Adverse Event
Time Frame: Up to 52 weeks
|
An Adverse Event (AE) is any untoward occurrence in a participant who is administered any pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding) symptom, or disease temporarily associated with the use of an IMP, whether or not it is related to the IMP.
|
Up to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Total Sleep Time at Week 52
Time Frame: Baseline and Week 52
|
Total Sleep Time (TST) is a subjective time recorded by the participant in an electronic sleep diary in response to the question "How much time did you actually spend sleeping?".
Baseline values were calculated by averaging baseline values from base trials P05706 and P05707.
Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged.
Missing values were imputed by the last observation carried forward (LOCF) method, where the last available assessments prior to the scheduled observation were averaged.
|
Baseline and Week 52
|
Change From Baseline in Sleep Latency at Week 52
Time Frame: Baseline and Week 52
|
Sleep Latency (SL) is the time from when the participant went to bed up to the the time the participant actually fell asleep, recorded by the participant in an electronic sleep diary.
Baseline values were calculated by averaging baseline values from base trials P05706 and P05707.
Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged.
Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged.
|
Baseline and Week 52
|
Change From Baseline in Wake Time After Sleep Onset at Week 52
Time Frame: Baseline and Week 52
|
Wake time after sleep onset (WASO) is, if the planned waking time is on or after the time of final awakening, as follows: total time from falling asleep to the time of planned wake up minus the total sleep time.
If the planned waking time is before the time of final awakening then WASO is as follows: total time from falling asleep to the time of actual final awakening minus the total sleep time.
All times were recorded by the participant in an electronic sleep diary.
Baseline values were calculated by averaging baseline values from base trials P05706 and P05707.
Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged.
Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged.
|
Baseline and Week 52
|
Change From Baseline in Number of Awakenings at Week 52
Time Frame: Baseline and Week 52
|
Number of awakenings is a subjective number recorded by the participant in an electronic sleep diary.
Baseline values were calculated by averaging baseline values from base trials P05706 and P05707.
Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged.
Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged.
|
Baseline and Week 52
|
Change From Baseline in Quality of Sleep Scale at Week 52
Time Frame: Baseline and Week 52
|
Quality of Sleep is a subjective number on a Visual Analog Scale recorded by the participant in an electronic sleep diary.
The scale ranges from 0 to 100, where very poor is rated at 0, up to excellent, rated at 100.
Baseline values were calculated by averaging baseline values from base trials P05706 and P05707.
Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged.
Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged.
|
Baseline and Week 52
|
Change From Baseline in Satisfaction With Sleep Duration Scale at Week 52
Time Frame: Baseline and Week 52
|
Satisfaction with Sleep Duration is a subjective number on a Visual Analog Scale recorded by the participant in an electronic sleep diary.
The scale ranges from 0 to 100, where very unsatisfied is rated at 0, up to fully satisfied, rated at 100.
Baseline values were calculated by averaging baseline values from base trials P05706 and P05707.
Data at baseline and at week 52 were collected every morning and evening for 7 consecutive days, and these data were then averaged.
Missing values were imputed by the LOCF method, where the last available assessments prior to the scheduled observation were averaged.
|
Baseline and Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2006
Primary Completion (Actual)
August 17, 2009
Study Completion (Actual)
August 17, 2009
Study Registration Dates
First Submitted
January 9, 2008
First Submitted That Met QC Criteria
January 28, 2008
First Posted (Estimate)
February 8, 2008
Study Record Updates
Last Update Posted (Actual)
October 3, 2018
Last Update Submitted That Met QC Criteria
September 4, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Adrenergic alpha-Antagonists
- Adrenergic alpha-2 Receptor Antagonists
- Mirtazapine
Other Study ID Numbers
- P05708
- 176004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
Leiden UniversityBioClock Consortium; Caring UniveristiesCompleted
-
National Science Council, TaiwanCompleted
-
Sunshine Lake Pharma Co., Ltd.Unknown
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Massachusetts General HospitalNational Institutes of Health (NIH)Completed
-
IpsenCompletedThe Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over (QUALISLEEP)InsomniaRussian Federation
-
Charite University, Berlin, GermanyCompleted
-
Roxane LaboratoriesCompleted
-
Butler HospitalSunovionCompleted
Clinical Trials on Org 50081
-
Weill Medical College of Cornell UniversityCompletedPsychotic Disorders | Major Depressive DisorderUnited States
-
Merck Sharp & Dohme LLCCompletedDepression | Psychotic Disorders | Depressive Disorders
-
Origo BiopharmaCompleted
-
Guangzhou General Hospital of Guangzhou Military...Guangdong Provincial Hospital of Traditional Chinese MedicineRecruiting
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedDepression | Psychotic Disorders | Depressive Disorders
-
Merck Sharp & Dohme LLCTerminated
-
Dennis CharneyNational Institutes of Health (NIH)WithdrawnMajor Depressive Disorder
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted